Bedrijfsoverzicht
Novartis AG is a Swiss-headquartered pharmaceutical entity that engages in the comprehensive research, development, manufacturing, distribution, marketing, and sale of medicinal products both domestically and internationally. The organization operates within the broader Healthcare sector, specifically categorized under the industry of Drug Manufacturers - General, which implies a focus on creating therapeutic solutions for various medical conditions rather than medical devices or biotechnology services alone. The company demonstrates a massive scale, evidenced by a current market capitalization of $297.35B, an annual revenue generated in the trailing twelve months of $56.67B, and a global workforce comprising 75267 employees. These substantial valuation and revenue figures indicate that Novartis holds a dominant position in the global pharmaceutical landscape, serving as a critical supplier of essential medicines such as Entresto for treating chronic heart failure with reduced ejection fraction. The sheer size of its operations and the breadth of its international distribution network underscore its capacity to influence therapeutic standards and maintain significant market share across diverse healthcare systems.
Financiële gezondheid
The company reports a trailing twelve-month revenue of $56.67B and a net income of $13.98B, with an EBITDA figure reaching $23.47B, highlighting a robust top-line performance despite underlying cost pressures. The significant gap between the $56.67B revenue and the $13.98B net income reveals a substantial cost structure where expenses, including cost of goods sold and operating expenditures, consume a considerable portion of total sales before arriving at the bottom line. Free cash flow stands at $12.12B, which provides the company with significant financial flexibility to fund ongoing research programs, manage debt obligations, and pursue strategic acquisitions without relying heavily on external capital markets. The gross margin sits at 76.0%, indicating highly efficient production and pricing power typical of branded pharmaceuticals, while the operating margin of 27.8% reflects the effectiveness of the company's overhead management and operational efficiency. The profit margin of 24.7% further confirms that a substantial portion of every dollar of revenue translates into actual profit for shareholders. In terms of liquidity, the company holds $11.53B in cash against $35.46B in debt, resulting in a debt-to-equity ratio of 76.17%, which suggests a leveraged balance sheet where debt obligations are significantly higher than equity capitalization. The current ratio is 1.12, indicating that the company possesses just enough current assets to cover its current liabilities, pointing to a tight but manageable short-term liquidity position. Return on Equity is 30.8% and Return on Assets is 11.1%, metrics that collectively reveal high management effectiveness in generating returns relative to the capital invested and the total asset base employed.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 21.55, while the forward P/E ratio is 15.67, a notable difference that implies the market expects earnings to grow significantly in the future to justify the lower forward multiple. The price-to-book ratio stands at 6.37, indicating that the stock trades at a substantial premium over its book value, reflecting the high intangible assets, patent portfolios, and brand value inherent in the pharmaceutical industry. Alternative valuation metrics such as the price-to-sales ratio of 5.25 and the EV/EBITDA of 13.56 suggest that the company is valued relative to its revenue and earnings power, providing a comprehensive view of its financial standing beyond just earnings multiples. The stock has exhibited a trading range over the past year with a 52-week high of $170.46 and a 52-week low of $104.93, placing the current price dynamics within a wide historical band that reflects periods of both expansion and contraction. The beta value of 0.52 indicates that the stock price exhibits lower volatility relative to the broader market, making it a less sensitive asset to general market fluctuations compared to high-beta technology or small-cap stocks.
Growth & Income
Revenue growth year-over-year is 2.2%, whereas earnings growth year-over-year is -11.6%, revealing that earnings are currently contracting at a rate significantly faster than revenue expansion. This divergence implies that cost increases, restructuring charges, or specific product declines are weighing heavily on profitability, causing the bottom line to underperform the top line in the current fiscal period. As a dividend payer, the company offers a dividend yield of 3.1% with a payout ratio of 55.9%, a level that appears sustainable given the strong free cash flow generation and the fact that the payout consumes less than two-thirds of the net income available to shareholders. The overall growth and income profile presents a mixed picture characterized by stable, albeit slow, revenue expansion supported by a healthy dividend yield, while earnings face temporary headwinds that suppress the bottom line growth trajectory.